Kuros Biosciences Reports Results for First Half 2018

Financial highlights
CHF 9.7 million cash at June 30
Operating expenses decreased to CHF 6.0 million

Operational highlights
First U.S. & European sales of MagnetOs
Commercial rollout in the U.S. and Europe on track
Preparation for Phase II clinical study of Fibrin-PTH in spine on track